VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2- early breast cancer (EBC)

Peter A Fasching ,Z Li,C Huang,Daniil Stroyakovskiy ,Sherene Loi ,Arlene Chan ,R Fresco ,Karen Afenjar ,Hope S Rugo ,Dennis J Slamon ,Bożena Kukiełka-Budny ,Andriy Danyliv ,Il Ferrusi ,Michael Untch ,Zbigniew Nowecki ,Sara A Hurvitz ,Denise A Yardley ,Miguel Martín ,Stephen Chia ,Gabriel N Hortobágyi

doi:10.1016/j.annonc.2023.08.007

VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2- early breast cancer (EBC)

Peter A Fasching , Z Li + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2023.08.007

Copy DOI

#Nonsteroidal Aromatase Inhibitor #Early Breast Cancer + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2- early breast cancer (EBC)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.